Mizuho upgraded Acadia Pharmaceuticals to Buy from Neutral with a price target of $35, up from $20.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ACAD:
- Acadia Pharmaceuticals price target raised to $42 from $39 at JMP Securities
- Acadia Pharmaceuticals sees FY23 NUPLAZID net sales $537.5M-$545M
- Acadia Pharmaceuticals sees Q4 DAYBUE net sales $80M-$87.5M
- Acadia Pharmaceuticals reports Q3 EPS (40c), consensus (43c)
- ACAD Earnings this Week: How Will it Perform?